Utreloxastat fails to slow ALS disease progression in Phase 2 trial
Twice-daily treatment with PTC Therapeutics’ oral candidate utreloxastat failed to significantly slow disease progression in adults with amyotrophic…
Articles by Margarida Maia, PhD
Lilly to develop ALS therapies against targets ID’d with Verge tech
Eli Lilly will develop therapies against two drug targets for amyotrophic lateral sclerosis (ALS) that were identified and…
First-in-human trial of ALS therapy ASHA-624 expected in early 2025
A newly awarded grant from the ALS Association will support Asha Therapeutics‘ work to advance ASHA-624, a small…
Mitochondrial genome mutations linked to ALS in genetic study
Mutations in the mitochondrial genome — the set of DNA instructions found inside mitochondria, the powerhouses of cells — may…
EMA’s CHMP upholds its negative opinion on masitinib for ALS
An advisory committee from the European Medicines Agency (EMA) has upheld its opinion against granting conditional marketing authorization to AB…
First SOD1-ALS patient dosed in trial of AMT-162 gene therapy
The first patient has been dosed in a Phase 1/2 clinical trial of AMT-162, the one-time gene therapy in development…
NeuroSense moving to request early approval of PrimeC in Canada
NeuroSense Therapeutics has initiated the process of applying to Canada’s regulators for early marketing approval of PrimeC in treating…
FGF4 shows benefits in ALS but fails to protect motor neurons
A growth factor called FGF4 can reduce the activity of astrocytes — star-shaped cells in the brain and spinal cord…
Phase 1 trial of prosetin to create digital twins of ALS patients
ProJenX has teamed up with Unlearn, a company that specializes in artificial intelligence (AI), to create…
MDA $500K research grant will support HEALEY ALS platform trial
The Muscular Dystrophy Association (MDA) has awarded a $500,000 research grant to a Massachusetts General Hospital scientist to support…